Prognostic Factors for Patients with Small-Cell Lung Cancer Treated with Chemoimmunotherapy: A Retrospective...

Area of Science:

• Oncology
• Medical Research

Background:

• Small-cell lung cancer (SCLC) with extensive-stage disease presents a significant therapeutic challenge.
• Chemoimmunotherapy has emerged as a treatment modality for extensive-stage SCLC.
• Predicting patient survival remains critical for treatment individualization.

Purpose of the Study:

• To identify prognostic factors for overall survival (OS) in extensive-stage SCLC patients treated with chemoimmunotherapy.
• To evaluate the association between identified prognostic factors and the incidence of immune-related adverse events (irAEs).

Main Methods:

• Patients were categorized into favorable (OS ≥ 24 months), moderate (6-24 months), and poor (< 6 months) survival groups.
• Multivariate Cox regression analyses were employed to determine independent prognostic factors.
• Laboratory markers including neutrophil/lymphocyte ratios and albumin levels were assessed.

Main Results:

• Liver metastasis and decreased albumin levels (<3.5 mg/dL) were identified as independent unfavorable prognostic factors for OS.
• Patients were stratified into three groups based on these factors, showing significant differences in OS (18.3 vs. 13.5 vs. 3.8 months; p < 0.001).
• A higher incidence of irAEs was observed in patients lacking these unfavorable prognostic factors (36% vs. 5%; p = 0.01).

Conclusions:

• Liver metastasis and hypoalbuminemia are significant independent predictors of poor prognosis in extensive-stage SCLC patients on chemoimmunotherapy.
• Patients without these unfavorable factors may experience better survival but face an increased risk of irAEs.
• These findings can inform clinical decision-making and patient management strategies.